Penumbra, Inc. (NYSE: PEN) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 79.66 | EPS (ttm) | 4.07 | Insider Own | 3.76% | Shs Outstand | 39.33M | Perf Week | 1.32% |
| Market Cap | 12.75B | Forward P/E | 53.27 | EPS next Y | 6.09 | Insider Trans | -0.17% | Shs Float | 38.23M | Perf Month | 1.88% |
| Enterprise Value | 12.76B | PEG | 4.25 | EPS next Q | - | Inst Own | - | Short Float | 5.55% | Perf Quarter | -0.13% |
| Income | 161.00M | P/S | 8.47 | EPS this Y | 18.31% | Inst Trans | - | Short Ratio | 4.86 | Perf Half Y | -9.18% |
| Sales | 1.50B | P/B | 8.33 | EPS next Y | 26.41% | ROA | 8.13% | Short Interest | 2.12M | Perf YTD | 4.28% |
| Book/sh | 38.93 | P/C | 62.21 | EPS next 5Y | 18.73% | ROE | 11.09% | 52W High | 362.42 -10.54% | Perf Year | 33.42% |
| Cash/sh | 5.21 | P/FCF | 58.51 | EPS past 3/5Y | - | ROIC | 8.40% | 52W Low | 221.27 46.53% | Perf 3Y | 5.25% |
| Dividend Est. | - | EV/EBITDA | 60.47 | Sales past 3/5Y | 18.35% 20.18% | Gross Margin | 67.84% | Volatility | 0.96% 0.63% | Perf 5Y | 24.11% |
| Dividend TTM | - | EV/Sales | 8.48 | EPS Y/Y TTM | 1030.56% | Oper. Margin | 12.45% | ATR (14) | 2.33 | Perf 10Y | 430.64% |
| Dividend Ex-Date | - | Quick Ratio | 3.86 | Sales Y/Y TTM | 25.94% | Profit Margin | 10.67% | RSI (14) | 68.27 | Recom | 2.59 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.75 | EPS Q/Q | -1.20% | SMA20 | 1.64% | Beta | 0.69 | Target Price | 347.00 |
| Payout | 0.00% | Debt/Eq | 0.15 | Sales Q/Q | 15.04% | SMA50 | 1.66% | Rel Volume | 0.89 | Prev Close | 323.02 |
| Employees | 4,700 | LT Debt/Eq | 0.14 | Earnings | Nov 04 | SMA200 | 2.50% | Avg Volume | 407.93K | Price | 324.22 |
| IPO Date | Sep 18, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -21.02% 1.16% | Net Debt/EBITDA | 0.04 | Volume | 363,249 | Change | 0.37% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $335 → $320 |
| May-07-26 | Reiterated | Evercore ISI Group | Outperform | $360 → $335 |
| Feb-26-26 | Reiterated | UBS | Buy | $335 → $374 |
| Jan-20-26 | Downgrade | Canaccord Genuity | Buy → Hold | $359 → $374 |
| Jan-20-26 | Downgrade | RBC Capital | Outperform → Sector Perform | $355 → $374 |
| Jan-16-26 | Reiterated | Robert W. Baird | $345 → $374 | |
| Jan-16-26 | Downgrade | Leerink Partners | Outperform → Market Perform | $263 → $374 |
| Jan-16-26 | Downgrade | Truist Securities | Buy → Hold | $370 → $374 |
| Jan-16-26 | Downgrade | Citigroup | Buy → Neutral | |
| Jan-16-26 | Downgrade | Needham | Buy → Hold |
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,505 | 1,404 | 1,195 | 1,059 | 847 | 748 | 560 | 547 | 445 | |
| Cost of Goods Sold Incl. D&A | 483 | 461 | 440 | 376 | 312 | 272 | 222 | 175 | 152 | |
| Gross Profit | 1,020 | 942 | 755 | 683 | 535 | 475 | 338 | 372 | 293 | |
| Selling, General and Administrative Excl. Other | 742 | 663 | 574 | 506 | 450 | 378 | 287 | 273 | 226 | |
| Research and Development | 92 | 90 | 95 | 84 | 79 | 105 | 90 | 52 | 36 | |
| Other Operating Expense | 0 | 0 | 77 | 19 | 0 | 0 | 0 | -1 | 31 | |
| Operating Income | 187 | 189 | 9 | 74 | 6 | -8 | -39 | 48 | -1 | |
| Interest Expense | 0 | 1 | 1 | 2 | 2 | 2 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 18 | 17 | 13 | 8 | 0 | -1 | 1 | 3 | 2 | |
| Net Income Before Taxes | 204 | 205 | 21 | 80 | 4 | -11 | -38 | 50 | 2 | |
| Income Taxes | 42 | 27 | 7 | -11 | 6 | -13 | -19 | 3 | -4 | |
| Consolidated Net Income | 161 | 178 | 14 | 91 | -2 | 5 | -16 | 48 | 7 | |
| Net Income From Continuing Operations | 126 | 178 | 14 | 91 | -2 | 3 | -19 | 47 | 6 | |
| Net Income | 161 | 178 | 14 | 91 | -2 | 5 | -16 | 48 | 7 | |
| EPS (Recurring) | 4.09 | 4.57 | 0.36 | 2.37 | -0.05 | 0.14 | -0.54 | 1.39 | 0.18 | |
| EPS (Basic, Before Extraordinaries) | 4.09 | 4.57 | 0.36 | 2.37 | -0.05 | 0.14 | -0.54 | 1.39 | 0.18 | |
| EPS (Diluted) | 4.07 | 4.52 | 0.36 | 2.32 | -0.05 | 0.14 | -0.54 | 1.34 | 0.18 | |
| EBITDA | 211 | 223 | 46 | 109 | 30 | 8 | -26 | 56 | 36 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 79.66 | 68.79 | 659.67 | 108.42 | — | 2,052.29 | — | 122.59 | 678.89 | |
| Price To Sales Ratio | 8.40 | 8.64 | 7.75 | 9.03 | 9.98 | 14.21 | 11.25 | 10.51 | 9.89 | |
| Gross Margin | 67.77 | 67.09 | 63.18 | 64.49 | 63.16 | 63.50 | 60.36 | 68.01 | 65.84 | |
| Operating Margin | 12.43 | 13.46 | 0.75 | 6.99 | 0.71 | -1.07 | -6.96 | 8.78 | -0.22 | |
| Net Margin | 10.70 | 12.68 | 1.17 | 8.59 | -0.24 | 0.67 | -2.86 | 8.78 | 1.57 | |
| Shares Outstanding | 39 | 39 | 39 | 38 | 38 | 37 | 36 | 35 | 36 | |
| Market Capitalization | 12,645 | 12,125 | 9,262 | 9,559 | 8,453 | 10,631 | 6,300 | 5,749 | 4,399 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Grewal Harpreet | Director | Apr 02 '26 | Sale | 328.22 | 100 | 32,822 | 8,719 | Apr 06 |
| Yuen Maggie | Chief Financial Officer | Mar 02 '26 | Sale | 342.30 | 2,432 | 832,474 | 18,353 | Mar 04 |
| Grewal Harpreet | Director | Jan 06 '26 | Sale | 312.64 | 186 | 58,151 | 8,230 | Jan 08 |
| Wilder Thomas | Director | Jan 02 '26 | Sale | 310.72 | 186 | 57,794 | 0 | Jan 06 |
| Bose Arani | Director | Dec 11 '25 | Sale | 308.82 | 15,000 | 4,632,293 | 258,462 | Dec 15 |
| Roberts Johanna | EVP, Gen. Counsel & Secretary | Dec 05 '25 | Sale | 300.13 | 300 | 90,039 | 63,836 | Dec 09 |
| Grewal Harpreet | Director | Dec 02 '25 | Sale | 292.98 | 100 | 29,298 | 8,416 | Dec 03 |
| Roberts Johanna | EVP, Gen. Counsel & Secretary | Dec 01 '25 | Sale | 294.94 | 600 | 176,967 | 64,136 | Dec 03 |
| Roberts Johanna | EVP, Gen. Counsel & Secretary | Nov 25 '25 | Sale | 300.06 | 1,800 | 540,108 | 64,736 | Nov 26 |
| Bose Arani | Director | Nov 25 '25 | Sale | 300.19 | 7,500 | 2,251,425 | 275,261 | Nov 26 |
| Bose Arani | Director | Nov 21 '25 | Sale | 290.56 | 7,500 | 2,179,213 | 282,761 | Nov 25 |
| Roberts Johanna | EVP, Gen. Counsel & Secretary | Nov 10 '25 | Sale | 266.98 | 600 | 160,189 | 63,657 | Nov 12 |
| Grewal Harpreet | Director | Nov 04 '25 | Sale | 227.58 | 186 | 42,330 | 8,516 | Nov 06 |
| Grewal Harpreet | Director | Oct 02 '25 | Sale | 248.61 | 186 | 46,241 | 8,702 | Oct 03 |
| Roberts Johanna | EVP, Gen. Counsel & Secretary | Oct 01 '25 | Sale | 249.70 | 600 | 149,822 | 64,257 | Oct 03 |